hosts the

9th International Symposium on
Translational Research in Oncology

Chairs: Professor John Crown
Professor Robert Kerbel (Toronto)

Friday September 30th & Saturday October 1st
Herbert Park Hotel, Ballsbridge, Dublin 4

Attendance is free but registration is required.

Register with: karen.culhane@ccrt.ie
Website: http://www.ccrt.ie
CPD accreditation: 9 CPD points

This is the 9th meeting in this series of symposia that was founded in 2001 by:
Dr. Dennis Slamon, UCLA and Professor John Crown, Dublin

The educational/scientific content of this meeting has been funded by third party sponsors. However, none of these sponsors had any influence over the agenda of the meeting.

In association with
9th International Symposium on Translational Research in Oncology

Chairs: Professor Robert Kerbel  
Professor John Crown

**Programme**

**Immunotherapy**

Friday, 30th September  
CPD Accreditation: 6 CPD points

**Development of immune therapies beyond PD-1 and CTLA-4 blockade**  
11:30-12:00  
Dr Mario Sznol, Professor of Medicine, Yale Cancer Centre

**Clinical Trials of Oxygenation Agents and Antagonists of A2a Adenosine Receptors to Enable Tumor Rejection by Immunotherapies of Cancer**  
12:00-12:30  
Prof Michail Siktkovsky, Eleanor W Black Chair, and Director of New England Inflammation and Tissue Protection. Northeastern University, Boston

**Talimogene laherparepvec, first approved oncolytic immunotherapy**  
12:30-1:00  
Dr Mark Shilkrut, Clinical Research Medical Director, Amgen Inc.

**Lunch**  
1:00-1:45

**Novel Therapies**

1:45-2:15  
**Title to be confirmed: on the topic of Ribociclib**  
Dr. Thomas Bachelot, MD, Head, Breast Cancer Unit and the Clinical Trial Unit, Centre Leon Berard, Lyon, France

2:15-2:45  
**Eribulin Mechanisms of Action: Beyond Antimitotic Effects to Complex Changes in Tumour Biology**  
Dr Bruce Littlefield, Head, Translational Medicine, Global Oncology Medical Affairs Eisai Inc.

**Angiogenesis**

2:45-3:15  
**The Biology of Angiogenesis and the Challenge of Identifying Anti-angiogenesis Biomarkers in Oncology**  
Dr Annette Byrne, Royal College of Surgeons in Ireland

3:15-3:45  
**“Implications of ‘vessel co-option’ by tumors for antiangiogenic therapy of metastatic disease”**  
Prof Robert Kerbel, Sunnybrook Health Science Centre, Toronto

3:45-4:00  
**Coffee break**

**Targeting Cell Signalling**

4:00-4:30  
**The PI3K pathway in cancer**  
Prof Bryan Hennessy, Royal College of Surgeons in Ireland

4:30-5:00  
**Targeting the IGF signaling network in cancer with the IGF-1/2 ligand neutralizing antibody BI 836845 – an update**  
Dr Thomas Bogenrieder, Global Clinical Program Leader, Boehringer Ingelheim

5:00-5:30  
**Neratinib for treatment of HER2 mutant, non-amplified breast cancers**  
Dr Alshad Lalani, Vice President, Translation Medicine, Puma Biotechnology Inc.

5:30-6:00  
**AZD2014 (Vistusertib) in breast cancer and other disease indications**  
Dr Christopher Shepherd, Principal Medical Scientist – Vistusertib and ERK, Associate Director, Clinical Research, AstraZeneca UK Limited

---

The educational/scientific content of this meeting has been funded by third party sponsors. However, none of these sponsors had any influence over the agenda of the meeting.
9th International Symposium on Translational Research in Oncology
Chairs: Prof John Crown and Prof Robert Kerbel
Saturday, 1st October  
CPD Accreditation: 3 CPD points

Personalized Cancer Medicine

9:00-9:30  
Title to be confirmed: Topic: Next generation sequencing and liquid biopsies  
Dr Christer Svedman, Senior Director Oncology Development, Genomic Health

9:30-10:00  
Hybrid-capture based liquid biopsy allows the detection of diverse genomic alterations  
Dr Judith Müller, NEO New Oncology

10:00-10:30  
HER2 Testing: Past and Present  
Prof Mike Press, Professor of Pathology, Harold E. Lee Chair in Cancer Research; Director of Breast Cancer Analysis Lab, Keck School of Medicine, University of Southern California

10:30-10:45  
Coffee break

DNA Damage/Repair

10:45-11:15  
Mutant p53 as a Target for the Treatment of Triple-Negative Breast Cancer  
Prof Joe Duffy, UCD Clinical Research Centre, St Vincent’s University Hospital

11:15-11:45  
Novel mechanisms in the DNA damage response  
Prof Noel Lowndes, Centre for Chromosome Biology, NUI, Galway

11:45-12:15  
Preclinical testing of VX-984, a DNA-PK inhibitor  
Dr. John Pollard, Head of Research Oncology, Vertex Pharmaceuticals

12:15-12:45  
Talazoparib Pharmacology: Clinical potential for PARP inhibition and PARP trapping  
Dr Andrew Proctor, Vice President of Preclinical Development, Medivation Inc.

12:45-1:45  
Lunch

Diversity/Genomic Instability

1:45-2:15  
Immune sculpting of the breast cancer genome  
Prof Lajos Pusztai, Professor of Medicine (Medical Oncology); Chief of Breast Medical Oncology; Co-Director, Yale Cancer Center Genetics, Genomics and Epigenetics Program

2:15-2:45  
Clonal Diversity and Genomic Drivers of Exceptional Responses  
Prof Michael Barrett, Associate Professor, Mayo Clinic Cancer Centre, Arizona

2:45-3:15  
DNA instability in solid tumours – the key to curing cancer?  
Prof Ken O’Byrne, Princess Alexandra Hospital, Queensland University of Technology

3:15-3:30  
Coffee break

Targeting Transcriptional Regulation

3:30-4:00  
Targeting the Vitamin D receptor in cancer  
Dr. Jean-François Dufour-Lamartinie, Chief Medical Officer, Hybrigenics

4:00-4:30  
Improving cancer therapy via CDK8/19 Mediator kinase  
Prof Igor Roninson, Director, Centre for Targeted Therapies, University of South Carolina

Targeting Cyclin Dependent Kinases

4:30-5:00  
Development of Palbociclib from Pre-clinical Assessment to Global Registration: A Paradigm for Development of CDK 4/6 Inhibitors  
Dr Rich Finn, Assistant Professor of Medicine, Geffen School of Medicine, UCLA

5:00-5:30  
Preclinical activity of abemaciclib as a single agent or in combination with anti-mitotic or targeted therapies for breast cancer  
Dr Neil O’Brien, Adjunct Assistant Professor, Department of Medicine, UCLA

The educational/scientific content of this meeting has been funded by third party sponsors. However, none of these sponsors had any influence over the agenda of the meeting.